Tarsus Pharmaceuticals

TARS · NASDAQ

$71.03+$1.53 (+2.20%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $69.50

TARS analyst rating

BuyConsensus of 8 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy8
Hold0
Underperform0
Sell0

12-month price target · 11 analysts

Average $101.55 (+43.0% upside)

Low: $84.84
Now: $71.03
High: $121.80

Upgrades and downgrades

The latest rating actions, newest first

TARS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Goldman Sachs	Sep 24, 2026	Initiates	Buy	$116.00	42%
Barclays	Sep 16, 2026	Initiates	Overweight	$110.00	53%
Jefferies	Sep 8, 2026	Maintains	Buy	$88.00 → $105.00	56%
Oppenheimer	Aug 12, 2026	Maintains	Outperform	$97.00 → $100.00	35%
Mizuho	Jul 31, 2026	Maintains	Outperform	$100.00 → $98.00	54%
Guggenheim	Jul 21, 2026	Maintains	Buy	$90.00 → $89.00	46%
HC Wainwright & Co.	Jul 9, 2026	Maintains	Buy	$88.00	47%
HC Wainwright & Co.	May 4, 2026	Maintains	Buy	$88.00	47%
Oppenheimer	Feb 25, 2026	Maintains	Outperform	$95.00 → $105.00	35%
Guggenheim	Feb 25, 2026	Maintains	Buy	$87.00 → $90.00	52%

The case for and against

Updated Oct 17, 2026

Bull case

Tarsus Pharmaceuticals is well positioned by XDEMVY’s strong commercial traction, with quarterly product sales above $100M and management guiding 2026 net product sales of approximately $670 million to $700 million, implying robust year-over-year growth of more than 50%. The outlook is supported by expanding prescription depth, patient awareness from the active DTC campaign, and the planned addition of 15-20 key account leaders by 2H26, all of which should deepen penetration into the estimated 9 million-patient opportunity. Beyond XDEMVY, the acquisition of iRenix and IRX-101 adds a second growth platform with positive Phase 2/3b data, including statistically significant reductions in pain and corneal staining, strengthening the long-term pipeline.

Bear case

Tarsus Pharmaceuticals is viewed negatively because the investment case depends heavily on XDEMVY achieving ambitious peak commercial revenue assumptions, yet prescription tracking and inventory normalization already suggest softer near-term demand, prompting a lower quarterly revenue estimate from $151.8M to $145.0M. Revenue recognition also lags prescriptions because it occurs when product is shipped into the channel, so a flat 1Q26 and the target of only 2.5 weeks of inventory imply limited momentum rather than accelerating sell-through. More broadly, the company remains exposed to financing risk and the uncertainty of continued development and commercialization, which is especially concerning for an early commercial-stage biopharmaceutical company.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.